Orthofix International (OFIX) Stock Forecast & Price Target

Orthofix Medical is attractive fundamentally because its Global Spine segment provides the majority of revenue and is anchored by recurring demand in bone growth therapies, spinal implants, biologics, and enabling technologies, while the Global Limb Reconstruction segment adds a differentiated portfolio in deformity correction, lengthening, fracture management, and preservation supported by digital tools. Although CMS’s reimbursement update for non-invasive bone growth stimulators effective on or after May 18, 2026 creates an estimated ~10% pressure within traditional Medicare and likely spills into portions of Medicare Advantage and commercial volume, the market reaction appears to overstate the permanence of the setback because the company’s core franchise remains clinically relevant and the reimbursement shock was introduced unusually quickly without a normal comment period. Even after the FY/26 guidance reduction and the company’s decision to abandon prior longer-range financial targets, the underlying investment case remains supported by Orthofix’s diversified orthopedic/spine platform, scale in Global Spine, and the possibility that an abrupt policy action may prove more manageable than the initial headline implies.

Orthofix Medical is facing a deteriorating fundamental outlook as management cut FY/26 revenue guidance by $12 million to $838-848 million and adjusted EBITDA guidance by $5 million to $90-93 million, while also stating that positive free cash flow is no longer expected in FY/26 and that longer-term financial targets, including mid-teen adjusted EBITDA margins by FY/28, are no longer applicable. The company’s preliminary Q1/26 revenue of $196.7 million was only modestly above estimates, but with an adjusted EBITDA estimate of just $9.2 million and Q1 expected to be the low water mark for both earnings and cash generation, profitability and liquidity appear under pressure despite revenue that is still only growing in the low single digits. Compounding the risk, the business remains heavily concentrated in Global Spine, which generates around 84% of revenue, leaving Orthofix exposed to segment-specific weakness and a non-traditional Medicare issue that management appears to be treating as near worst-case in FY/26.